CL2011002525A1 - Uso de compuesto derivado de quinazolindiona para tratar una enfermedad cardiovascular. - Google Patents

Uso de compuesto derivado de quinazolindiona para tratar una enfermedad cardiovascular.

Info

Publication number
CL2011002525A1
CL2011002525A1 CL2011002525A CL2011002525A CL2011002525A1 CL 2011002525 A1 CL2011002525 A1 CL 2011002525A1 CL 2011002525 A CL2011002525 A CL 2011002525A CL 2011002525 A CL2011002525 A CL 2011002525A CL 2011002525 A1 CL2011002525 A1 CL 2011002525A1
Authority
CL
Chile
Prior art keywords
quinazolindione
cardiovascular disease
derived compound
treat cardiovascular
treat
Prior art date
Application number
CL2011002525A
Other languages
English (en)
Inventor
Fabrice Viviani
Philip Janiak
Gilbert Marciniak
Jean-Francois Nave
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2011002525A1 publication Critical patent/CL2011002525A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2011002525A 2009-04-09 2011-10-07 Uso de compuesto derivado de quinazolindiona para tratar una enfermedad cardiovascular. CL2011002525A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0901755A FR2944206B1 (fr) 2009-04-09 2009-04-09 Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione

Publications (1)

Publication Number Publication Date
CL2011002525A1 true CL2011002525A1 (es) 2012-02-17

Family

ID=41181038

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002525A CL2011002525A1 (es) 2009-04-09 2011-10-07 Uso de compuesto derivado de quinazolindiona para tratar una enfermedad cardiovascular.

Country Status (35)

Country Link
US (1) US8846654B2 (es)
EP (1) EP2416777B1 (es)
JP (1) JP5685578B2 (es)
KR (1) KR101686267B1 (es)
CN (1) CN102458409B (es)
AR (1) AR076232A1 (es)
AU (1) AU2010233596B2 (es)
BR (1) BRPI1010256A2 (es)
CA (1) CA2758234A1 (es)
CL (1) CL2011002525A1 (es)
CO (1) CO6440577A2 (es)
CR (1) CR20110527A (es)
CY (1) CY1115987T1 (es)
DK (1) DK2416777T3 (es)
DO (1) DOP2011000306A (es)
EA (1) EA020984B1 (es)
EC (1) ECSP11011377A (es)
ES (1) ES2528633T3 (es)
FR (1) FR2944206B1 (es)
HK (1) HK1165997A1 (es)
HR (1) HRP20150106T1 (es)
HU (1) HUE024161T2 (es)
IL (1) IL215610A (es)
MA (1) MA33254B1 (es)
MX (1) MX2011010645A (es)
NI (1) NI201100180A (es)
NZ (1) NZ595660A (es)
PL (1) PL2416777T3 (es)
PT (1) PT2416777E (es)
SG (2) SG175131A1 (es)
SI (1) SI2416777T1 (es)
TN (1) TN2011000506A1 (es)
TW (1) TWI457330B (es)
UY (1) UY32555A (es)
WO (1) WO2010116090A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2944282B1 (fr) * 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
US9499496B2 (en) 2012-06-05 2016-11-22 University Of Kansas Inhibitors of respiratory syncytial virus
US9951038B2 (en) 2012-12-27 2018-04-24 Purdue Pharma L.P. Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3879393A (en) * 1973-06-18 1975-04-22 Miles Lab Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones
JPS56164172A (en) * 1980-05-22 1981-12-17 Masayuki Ishikawa Novel 2,4 1h,3h -quinazolinedione derivative
EP0040793B1 (en) * 1980-05-22 1985-08-28 Masayuki Ishikawa Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
EP0638567A4 (en) 1993-02-18 1995-05-10 Kyowa Hakko Kogyo Kk ADENOSINE INHIBITORS.
HUP0101793A3 (en) 1998-04-20 2003-02-28 Fujisawa Pharmaceutical Co Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
WO2001044228A2 (fr) 1999-12-14 2001-06-21 Sanofi-Synthelabo Derives de quinazolinedione et phtalimide, leurs preparations et leurs applications en therapeutique
WO2006092692A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
MX2007010721A (es) 2005-03-01 2007-11-13 Pfizer Ltd Nuevo uso de inhibidores de fosfodiesterasa 7 para el tratamiento de dolor neuropatico.
WO2007067946A2 (en) 2005-12-07 2007-06-14 The Regents Of The University Of California Diagnosis and treatment of chronic lymphocytic leukemia (cll)
MX2009010450A (es) 2007-03-27 2009-11-23 Omeros Corp El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento.
JPWO2008133155A1 (ja) 2007-04-19 2010-07-22 アステラス製薬株式会社 二環式ヘテロ環化合物
FR2921926B1 (fr) * 2007-10-03 2009-12-04 Sanofi Aventis Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.
FR2943673B1 (fr) * 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione

Also Published As

Publication number Publication date
PT2416777E (pt) 2015-02-04
FR2944206B1 (fr) 2012-12-28
TN2011000506A1 (fr) 2013-05-24
HRP20150106T1 (hr) 2015-05-08
FR2944206A1 (fr) 2010-10-15
BRPI1010256A2 (pt) 2016-03-22
UY32555A (es) 2010-11-30
EA201171229A1 (ru) 2012-12-28
SG10201400420PA (en) 2014-05-29
EP2416777B1 (fr) 2014-11-12
KR101686267B1 (ko) 2016-12-13
PL2416777T3 (pl) 2015-05-29
KR20120005499A (ko) 2012-01-16
AR076232A1 (es) 2011-05-26
JP2012523398A (ja) 2012-10-04
DK2416777T3 (en) 2015-02-09
HK1165997A1 (en) 2012-10-19
EA020984B1 (ru) 2015-03-31
WO2010116090A1 (fr) 2010-10-14
AU2010233596A1 (en) 2011-11-03
TW201040155A (en) 2010-11-16
ES2528633T3 (es) 2015-02-11
TWI457330B (zh) 2014-10-21
NI201100180A (es) 2012-01-11
US20120184522A1 (en) 2012-07-19
AU2010233596B2 (en) 2016-06-23
MX2011010645A (es) 2012-01-19
CY1115987T1 (el) 2017-01-25
CN102458409A (zh) 2012-05-16
DOP2011000306A (es) 2011-10-31
CA2758234A1 (fr) 2010-10-14
CR20110527A (es) 2014-05-12
IL215610A (en) 2013-07-31
ECSP11011377A (es) 2011-11-30
CO6440577A2 (es) 2012-05-15
CN102458409B (zh) 2014-06-18
SG175131A1 (en) 2011-11-28
NZ595660A (en) 2013-03-28
JP5685578B2 (ja) 2015-03-18
US8846654B2 (en) 2014-09-30
MA33254B1 (fr) 2012-05-02
SI2416777T1 (sl) 2015-02-27
IL215610A0 (en) 2011-12-29
EP2416777A1 (fr) 2012-02-15
HUE024161T2 (hu) 2016-02-29

Similar Documents

Publication Publication Date Title
SMT201500053B (it) 2-Amminobenzimidazol-5-carbossammidi come agenti nati-infiammatori
DK2364293T3 (da) Hidtil ukendte pyrazol-4-N-alkoxycarboxamider som mikrobiocider
DK3138854T3 (da) Antistoffer mod CD40
BRPI0912213A2 (pt) preparação cosmética
BRPI1014956A2 (pt) agentes antinflamatórios.
ES2397671T8 (es) Procedimiento para preparar voriconazol
BRPI0908428A2 (pt) uso de ranozalina para tratar a dor.
BRPI0914614A2 (pt) 2-arilaminoquinazolinas para tratar doenças proliferativas
BRPI0922804A8 (pt) formas de dosagem sólidas de bendamustina
BRPI0909488A2 (pt) brocha
UY33156A (es) Nuevos compuestos tienopirrol
BRPI1014388A2 (pt) preparação de sólido.
BRPI0921679A2 (pt) composto útil para tratar celulite
DK2453858T3 (da) Fremgangsmåde
BRPI1016245A2 (pt) Preparação de c-pirazina-metilaminas.
BRPI0822264A2 (pt) Dapsona para tratar rosácea
ITTO20110268A1 (it) Composizione di maquillage.
BRPI1006968A2 (pt) microbiocidas
BRPI1007471A2 (pt) composições de enxágue para cuidados pessoais
CL2011002525A1 (es) Uso de compuesto derivado de quinazolindiona para tratar una enfermedad cardiovascular.
BRPI0915761A2 (pt) composto de heterociclila para tratamento de doença cardiovascular
DK2173197T3 (da) Fremgangsmåde
BRPI1013788A8 (pt) uso de monocloroupéia para tratar águas industriais.
BRPI0822637A2 (pt) Uso de lanosta-8, 24-dien-3-óis
BR112012002267A2 (pt) compostos para o tratamento de inflamação.